Weekly long-term intravenous immunoglobulin for refractory parvovirus B19 and Epstein-Barr virus-induced immune thrombocytopenic purpura.
In pediatric acute immune thrombocytopenic purpura (ITP) cases, it is usually possible to determine an underlying pathology; among them, viral infections are the leading causative agents. In this report, we describe two cases of acute ITP complicated secondary to parvovirus B19 or Epstein-Barr virus (EBV) infections who were unresponsive to initial therapeutic measures, but who responded to long-term intravenous immunoglobulin (IVIG) treatment, given weekly for five to eight weeks.
Tavil
Betül
B
Pediatric Hematology Unit, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Unal
Sule
S
Aytaç-Elmas
Selin
S
Yetgin
Sevgi
S
D002648:Child; D002675:Child, Preschool; D020031:Epstein-Barr Virus Infections / Q000150:complications*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007155:Immunologic Factors / Q000008:administration & dosage*; D008297:Male; D010322:Parvoviridae Infections / Q000150:complications*; D016732:Parvovirus B19, Human; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology*
D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors